Literature DB >> 3032885

Cefodizime (HR 221) potentiation of human neutrophil oxygen-independent bactericidal activity.

M T Labro, N Amit, C Babin-Chevaye, J Hakim.   

Abstract

The enhanced bactericidal activity of human neutrophils induced by cefotaxime and cefodizime, two methoxy-imino-amino- 2-thiazolyl cephalosporins, is linked to the cell stimulation of oxygen-dependent and oxygen-independent killing systems, respectively. Cefotaxime enhances both the killing and the oxidative response of neutrophils to opsonized particulate stimuli (bacteria for both activities and opsonized zymosan for the oxidative burst). These effects were not observed with non-opsonized particles (bacteria or zymosan) or soluble stimuli. On the contrary, cefodizime enhances killing of opsonized and non-opsonized bacteria by neutrophils regardless of treatment with phenylbutazone which blocks neutrophil oxidative metabolism. Cefodizime does not universally alter the oxidative burst induced by various stimuli, but has been shown to enhance the bactericidal activity of crude extracts of neutrophil granules. The data suggest that cefodizime and non O2-dependent killing systems of neutrophils cooperate in killing bacteria.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3032885     DOI: 10.1093/jac/19.3.331

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

Review 1.  Effects of anti-infectious agents on polymorphonuclear neutrophils.

Authors:  M T Labro; J el Benna
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

2.  In vitro effect of cefodizime, imipenem/cilastatin and co-trimoxazole on dexamethasone and cyclosporin A depressed phagocytosis.

Authors:  A Dhondt; R Vanholder; M A Waterloos; G Glorieux; R De Smet; S Ringoir
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

Review 3.  Immunomodulating effects of antibiotics: literature review.

Authors:  B Van Vlem; R Vanholder; P De Paepe; D Vogelaers; S Ringoir
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

4.  Prospective randomized comparison of cefodizime versus cefuroxime for perioperative prophylaxis in patients undergoing coronary artery bypass grafting.

Authors:  C Wenisch; A Bartunek; K Zedtwitz-Liebenstein; M Hiesmayr; B Parschalk; T Pernerstorfer; W Graninger
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

5.  Influence of cefodizime on pulmonary inflammatory response to heat-killed Klebsiella pneumoniae in mice.

Authors:  Y Bergeron; A M Deslauriers; N Ouellet; M C Gauthier; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

6.  Cefodizime host-defence enhancement: considerations of dose-response relationships in healthy volunteers.

Authors:  G Gialdroni Grassi; P M Shah
Journal:  Infection       Date:  1992       Impact factor: 3.553

7.  Immunopharmacological activity of cefodizime in young and elderly subjects: in vitro and ex vivo studies.

Authors:  P L Meroni; F Capsoni; M O Borghi; W Barcellini; F Minonzio; A M Ongari; C Fain; C Hu; G Brambilla; C Pettenati
Journal:  Infection       Date:  1992       Impact factor: 3.553

Review 8.  Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; R N Brogden
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

9.  Pharmacokinetics of cefodizime following single doses of 0.5, 1.0, 2.0, and 3.0 grams administered intravenously to healthy volunteers.

Authors:  B Lenfant; F Namour; C Logeais; D Coussediere; O Rivault; A Bryskier; A Surjus
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

10.  Effect of cefodizime and ceftriaxone on phagocytic function in patients with severe infections.

Authors:  C Wenisch; B Parschalk; M Hasenhündl; E Wiesinger; W Graninger
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.